Detalles de la búsqueda
1.
A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis.
J Am Acad Dermatol
; 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38685404
2.
Unusual location of tuberculosis in the course of tumor necrosis factor α inhibitor therapy.
Reumatologia
; 53(3): 161-4, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-27407244
3.
Atypical course of Henoch-Schonlein purpura in an adult patient.
Reumatologia
; 53(4): 225-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-27407252
4.
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Arthritis Rheumatol
; 69(2): 277-290, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27860410
5.
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
Arthritis Res Ther
; 18: 82, 2016 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27038608
6.
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Arthritis Res Ther
; 18: 25, 2016 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26795209
7.
Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
J Rheumatol
; 34(2): 408-20, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17304660
Resultados
1 -
7
de 7
1
Próxima >
>>